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Open access under the ElsBackground: Major depression is a frequent adverse effect of interferon-alpha (IFN-a) therapy. Although
the indoleamine 2,3-dioxygenase (IDO) enzyme seems to be involved in the pathophysiology of IFN-a-
induced depression, no pharmacogenetic study has investigated whether variation in the IDO gene mod-
iﬁes vulnerability to this adverse effect.
Methods: A cross-sectional study assessing 277 hepatitis C patients recruited in two specialized outpa-
tient clinics of Brazil. They were interviewed with the Mini International Neuropsychiatric Interview
(MINI) approximately 1 month after the end of IFN-a plus ribavirin therapy. Genomic DNA of individuals
was extracted from venous blood. Three IDO single-nucleotide polymorphisms (SNPs) were genotyped
(rs3824259; rs10089084 and rs35099072).
Results: MINI indicated that 21.3% of the sample met criteria for a major depressive episode during the
course of IFN-a therapy. No association with the diagnosis of a major depressive episode during the
course of IFN-a therapy was observed genotype or allele-wise (p > 0.05). Current major depression
and/or current anxiety disorder was signiﬁcantly associated with IFN-a-related depression (p < 0.005).
However, gender, age, route of infection, result of the antiviral treatment, past history of substance use
disorders, depression or any other psychiatric disorder showed no association with IFN-a-related
depression (p > 0.05).
Conclusions: Our results suggest no inﬂuence of the variants in the IDO gene and the diagnosis of inter-
feron-a-related depression in the Brazilian population. Interferon-a-related depression may impose per-
sistent psychopathology on at least 15% of the depressed patients even 2 years after antiviral therapy
termination. The cross-sectional design is a limitation of our study, predisposing memory bias. Prospec-
tive pharmacogenetic studies are warranted to continue investigation of the impact of IDO polymor-
phisms on the development of IFN-a-induced depression.
 2011 Elsevier Inc. Open access under the Elsevier OA license. 1. Introduction with ribavirin (RBV). This treatment offers the opportunity for cureChronic hepatitis C affects over 170 million individuals world-
wide (Capuron et al., 2002; Asnis et al., 2003; Asnis and De La
Garza, 2006; Hauser et al., 2000; Keefe, 2007). The gold standard
treatment for hepatitis C is interferon-alpha (IFN-a) combinedário Professor Edgard Santos,
a Psiquiatria, 3. Andar – CEP
111.
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evier OA license. in more than 50% of hepatitis C virus (HCV)-infected patients
(Asnis and De La Garza, 2006). However, IFN-a-induced major
depression episodes (MDEs) are a frequent adverse effect in 30–
45% of patients who receive this treatment (Capuron et al., 2002;
Asnis et al., 2003). This IFN-a-related neuropsychiatric side effect
may lead to severe outcomes such as suicidal behavior, therapy
withdrawal, and poor virological response (Capuron et al., 2002;
Raison et al., 2007; Leutscher et al., 2010).
The primary pathophysiological hypothesis for IFN-a-induced
depression involves the interaction between immune and central
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pro-inﬂammatory cytokines, which are important for viral clear-
ance in the therapy of HCV, but which also mediate the ‘‘sickness
behavior’’, characterized by loss of appetite, sleep disturbance,
fatigue, malaise, lethargy, inability to concentrate, and loss of
interest in the surroundings (Asnis et al., 2003; Raison et al.,
2005; Quarantini et al., 2007). These features overlap with depres-
sive symptoms, which explain why non-mental-health profession-
als may fail to promptly diagnose this adverse effect, thus resulting
in additional damage to HCV patients, including chronic or recur-
rent depression (Galvão-de Almeida et al., 2010a,b).
Apart from the possible direct actions of proinﬂammatory cyto-
kines in the brain, it seems they modulate the serotonergic system
through the upregulation of the indoleamine 2,3-dioxygenase
enzyme (IDO). IDO over-stimulation may result in lower plasma
concentrations of tryptophan, and consequently in decreased
availability of serotonin, one of the neurotransmitters implicated
in pathophysiology of major depression, in the central nervous
system (CNS) (Wichers and Maes, 2002; Bonaccorso et al., 2002;
Capuron and Miller, 2004; Comai et al., 2011). This mechanism
may also result in higher production of kynurenine, another tryp-
tophan metabolite, the metabolites of which (i.e., quinolinic acid,
and 3-hydroxykynurenine) have been demonstrated to be involved
in such degenerative diseases as Alzheimer’s and amyotrophic lat-
eral sclerosis, as well as in depression and schizophrenia (Chen
et al., 2010; Maes, 2010).
These hypotheses are additionally supported by such clinical
ﬁndings as reduced acid 5-hydroxy-indoleacetic acid (5-HIAA) in
the cerebrospinal ﬂuid of patients treated with IFN-a, and by the
efﬁcacy of selective serotonin reuptake inhibitors (SSRIs) in the
treatment of IFN-a-induced depression (Capuron and Miller,
2004; Vignau et al., 2005). The involvement of IDO is also corrob-
orated by a study in which untreated depressed patients, during
IFN-a use, displayed a signiﬁcant increase in serum kynurenine,
and more prolonged reductions in tryptophan concentrations than
those not depressed during the same treatment (Capuron and
Miller, 2004).
Considering that the HCV-major depression comorbidity
remains under-diagnosed (Batista-Neves et al., 2008) and affects
both the quality of life and the course of the somatic illnesses
(Batista-Neves et al., 2009), many authors have suggested system-
atically treating IFN-a-induced depression prophylactically with
antidepressants (Raison et al., 2007; Musselman et al., 2001;
Schaefer et al., 2005; Kraus et al., 2005; Gleason et al., 2007;
Morasco et al., 2007). A recent review of six clinical trials by our
group did not support this strategy (Galvão-de Almeida et al.,
2010a,b). Thus, risk factors for depression during IFN-a treat-
ment in HCV individuals need to be identiﬁed.
Recent studies (Bull et al., 2009; Lotrich et al., 2009; Pier-
ucci-Lagha et al., 2010) have suggested that genetic evaluation
may be informative for screening ‘‘at-risk’’ HCV patients and may
produce more successful individualized preventive and therapeu-
tic approaches. Considering the signiﬁcant role played by IDO in
the regulation of serotonin levels during IFN-a treatment and its
possible inﬂuence on IFN-a-induced depression, variation in IDO
gene may inﬂuence risk of developing treatment-induced depres-
sion. To test this hypothesis, we conducted an association study
with three IDO functional polymorphisms and the diagnosis of ma-
jor depression during the course of IFN-a plus RBV therapy in HCV
patients.2. Methods and Materials
A cross-sectional study was performed evaluating the
association of three functional polymorphisms in IDO gene andthe diagnosis of IFN-a-related depression in HCV patients who
had completed IFN-a plus RBV therapy.
2.1. Sample
The sample comprised HCV patients recruited between Febru-
ary 2008 and March 2010 from the outpatient of the Hepatology
clinics of the Teaching Hospital, Federal University of Bahia (UFBA),
Bahia, Brazil, and the São Paulo Hospital, Federal University of São
Paulo (UNIFESP), São Paulo, Brazil.
Initially, medical charts were screened in order to select poten-
tial subjects. Sequentially, the patients that had fulﬁlled the inclu-
sion and exclusion criteria were invited, personally during the
regular medical appointments or by phone, to participate.
Inclusion criteria included: 1. Age between 18 and 65; 2. Diag-
nosis of chronic hepatitis C with anti-HCV positive by ELISA III, and
conﬁrmed by qualitative determination of HCV RNA; 3. Treatment
with conventional or pegylated IFN-a plus RBV for at least
3 months (if discontinued due to lack of efﬁcacy); 4. Therapy
termination at least 1 month prior to evaluation.
Exclusion criteria were: 1. Co-infections (hepatitis B virus- HBV;
human immunodeﬁciency virus- HIV; human T lymphotropic
virus- HTLV); 2. Decompensated liver disease (Child-Pugh B or
C); 3. Diagnoses of other causes of liver disease than hepatitis C;
4. Decompensated general medical conditions (e.g., patients with
a recent diagnosis of hypertension/diabetes, or with unstable clin-
ical status - i.e., high blood pressure or high glycemia despite reg-
ular use of speciﬁc therapy); 5. Neurological conditions (epilepsy,
Parkinson’s Disease, past history of cerebrovascular events); 6.
Cancer diagnosis; 7. Previous diagnosis (before initiation of antivi-
ral therapy) of major depression, schizophrenia, bipolar disorder,
organic mental disorder, or moderate to severe mental retardation;
8. Difﬁculty understanding the study and its objectives.
2.2. Phenotypic assessment
After the complete antiviral therapy, the HCV patients were
cross-sectionally assessed with a comprehensive interview. It
included a sociodemographic and clinical characteristics question-
naire, a structured psychiatric diagnostic interview and two psy-
chiatric symptoms severity scales.
Assessed clinical features included the probable route of infec-
tion, viral genotype, hepatic ﬁbrosis according to the METAVIR
classiﬁcation (Bedossa and Poynard, 1996), and family psychiatric
history. Medical charts were also consulted in order to guarantee
the best available information.
Lifetime psychiatric diagnoses were evaluated by the Mini
International Neuropsychiatric Interview, Brazilian version 5.0.0
(MINI Plus) (Amorim, 2000), which encompasses the main axis I
disorders of DSM-IV (American Psychiatric Association, 1994),
and International Classiﬁcation of Diseases (World Health Organi-
zation, 1991). Beck Depression Inventory (BDI) (Beck et al., 1961),
and Hospital Anxiety and Depression Scale (HADS; Brazilian
version) (Botega et al., 1995) were used to assess the severity of
depressive and anxiety symptoms.
The minimum time for the assessment, after the end of IFN-a
plus RBV treatment, was set at 1 month but was not given a
deadline.
2.3. Genotypic assessment
2.3.1. DNA Extraction
Genomic DNA of individuals was extracted from samples of
5 ml of peripheral venous blood using the ‘‘salting out’’ method
and stored in individual tubes labeled for later analysis (Miller
et al., 1988).
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Genotyping
To comprehensively screen the IDO gene, the Tagger program
(http://www.broad.mit.edu/mpg/tagger/) (de Bakker et al., 2005)
from the HapMap Project database (http://www.hapmap.org/
index.html.en) (The International HapMap Consortium, 2003) for
the CEU population (Individuals with European ancestry) was used
in the Tagger Pairwise mode. Minor allele frequency cutoff was set
at 0.05 and r2 cutoff was set at 0.7. Two tag single-nucleotide poly-
morphisms (SNPs) (rs3824259; rs10089084) located in the 5’ re-
gion of the IDO gene, capturing a total of 5 of the 7 existing SNPs
in the IDO gene, exhibiting a minor allele frequency higher than
5%, were selected. According to the database, the two selected SNPs
are representative of the common genetic variation in the gene,
since they work as proxy markers for the other untyped SNPs in
the region, with a mean r2 value of 0.916. The third SNP selected
in this study (rs35099072) was chosen based on its potential func-
tional properties. Arefayene et al. (2009) recently demonstrated
that this polymorphism resulted in signiﬁcantly reduced protein
expression and enzyme activity. Genotyping was performed by
Prevention Genetics (Marshﬁled, MA, USA) using allele-speciﬁc
PCR with universal energy transfer-labeled primers (Myakishev
et al., 2001).
Additionally, a set of 35 ancestry informative markers (AIMs),
which exhibit a high level of allele frequency difference among
the three founder populations of the Brazilian individuals (Europe-
ans, West-Africans and Native Americans) (Shriver et al., 2005;
Guindalini et al., 2006), were selected for genetic admixture
analyzes. The number of ancestral populations (K) among the sam-
ple and individual admixture proportions was estimated using the
Bayesian Markov Chain–Monte Carlo (MCMC) method imple-
mented in the STRUCTURE 2.1 program (Pritchard et al., 2000).
The program was run under the admixture model, using correlated
allele frequencies and no prior population information with a
burn-in of 100,000 interactions and 1000,000 interactions after
burn-in. Genotyping of all markers was performed using the same
method described above. Only genotypes with a level of conﬁ-
denceP90% were included in the analysis.
2.4. Statistical analysis
Student’s T tests and Fisher’s exact test were used to test for dif-
ferences between groups in sociodemographic and clinical fea-
tures. Fisher exact test was performed for analysis of categorical
variables. Continuous data were evaluated with T tests and pre-
sented as mean ± S.D. (standard deviation). The odds ratios and
95% conﬁdence intervals for the genotypic analyses were derived
from multivariate logistic regression models using the Statistical
Package for the Social Sciences (SPSS) v15.0. Two-tailed hypotheses
were used with a statistical signiﬁcance level set at p < 0.05.
2.4.1. Ethical Aspects
The study was approved by the Medical Review Ethics Commit-
tees of UFBA and UNIFESP and performed in accordance with the
ethical standards set in the 1996 Declaration of Helsinki, and with
Resolution 196/96 on research involving human subjects. All
patients had provided written informed consent prior to their
inclusion in the study.3. Results
During the ﬁrst stage of the study, 759 medical charts were
screened. Two hundred and thirty-six HCV subjects were excluded
because they had never been treated, 17 were older than 65, 4 had
only been treated with IFN-a (without RBV; e.g., chronic renalfailure and sickle cell anemia), 5 patients had schizophrenia, 2
had bipolar disorder, 4 had already been diagnosed with depres-
sion, 20 were excluded for co-infections, 12 for neurological condi-
tions, 7 for cancer, and 9 were classiﬁed as Child-Pugh B. Finally,
412 patients were eligible to participate in the study: 113 could
not be contacted for the second screening; 4 demonstrated some
intellectual deﬁcit and were therefore unable to understand the
purpose of the study; and 27 refused to participate. Two hundred
and ninety-nine interviews were ultimately performed, but 22 pro-
tocols could not be completed.
3.1. Demographic and Clinical Characteristics of the Total Study
Sample
The sample of 277 patients was predominantly made up of
males (56.7%), presented a mean age of 51.3 years (standard devi-
ation [SD]: 7.7), and a mean duration of chronic HCV diagnosis of
6.4 years (SD: 3.7). Thirty-four percent of the patients had been
infected through blood transfusion, and of those who acquired
HCV sharing syringes, 69% did so to use vitamin complex injec-
tions. Almost 75% of the sample had acquired genotype 1 HCV,
and 81.5% had been treated with pegylated IFN-a. The most com-
mon co-occurring diseases were systemic arterial hypertension
(32.1%), diabetes mellitus (17%), and hepatic cirrhosis (15.9%). Ta-
ble 1 summarizes the characteristics of the individuals who met
criteria for a major depressive episode during the course of IFN-a
therapy. The level of ﬁbrosis revealed by the hepatic biopsy was
the only variable associated with the diagnosis of IFN-a-related
depression (p = 0.03).
3.2. Psychiatric and Psychometric Characteristics of the Total Study
Sample
Regarding psychiatric features, MINI indicated that 21.3% of the
sample met criteria for a major depressive episode during the
course of IFN-a therapy, 10.1% met criteria for lifetime major
depressive episode with no relation to IFN-a exposure, and 4.7%
of the patients were depressed at the time of the evaluation. The
mean current scores of BDI and HADS were, respectively,
11.2 ± 10.0, and 11.4 ± 7.7. Approximately 18% of the patients re-
ferred to a current or past psychiatric treatment, 17.7% fulﬁlled cri-
teria for lifetime anxiety disorder, and 35.7% for lifetime substance
abuse or dependence.
Table 2 summarizes the data concerning the psychiatric disor-
ders detected, personal and family psychiatric history, and the psy-
chometric measures in the groups of individuals with and without
IFN-a-related depression. Current major depression and/or current
anxiety disorder was signiﬁcantly associated with IFN-a-related
depression (p < 0.005). However, lifetime major depression non-
related to IFN-a and lifetime substance use disorders showed no
association with IFN-a-related depression (p > 0.05). The current
anxiety disorders associated with the diagnosis of IFN-a-related
depression were generalized anxiety disorder (GAD) (p = 0.03),
and speciﬁc phobia (p = 0.003). The only past anxiety disorder with
a statistically signiﬁcant correlation was panic disorder (p = 0.04)
although only 2 patients presented with this diagnosis.
3.3. Genetic analyses
The observed genotype frequencies for the rs3824259;
rs10089084 and rs35099072 SNPs were demonstrated in Hardy–
Weinberg Equilibrium in our sample (p > 0.05). Based on the
genotypic data of the 35 AIMs, for the sample as a whole, the
STRUCTURE 2.1 program estimated the mean ancestry proportions
of the individuals to be: 53.5 ± 19.3% European, 29.1 ± 18.8%
West-African, and 17.3 ± 10.9% Native American. The ancestry
Table 1
Sociodemographic and clinical characteristics of the patients concerning their IFN-a-related depression status, according to the MINI.
Characteristics IFN-a-related depression p value
Yes No
Age in years (mean ± SD) 50.9 ± 7.0 51.4 ± 7.9 0.67
Male gender% (N) 52.5% (31) 57.8% (126) 0.55
Marital Status% (N)
Stable marital relationship 66.1% (39) 72.5% (158) 0.33
Education% (N)
Complete high school degree 49.2% (29) 42.2% (92) 0.37
Occupational status% (N)
Employed, student or housekeeper 52.5% (31) 59.2% (129) 0.37
Paid activity, source of income 71.2% (42) 82.1% (179) 0.07
Probable Route of Infection% (N)
Transfusion 39% (23) 32.1% (70)
Tattoo 3.4% (2) 5.0% (11)
Sharing needles or straws for drug use 13.6% (8) 16.5% (36)
Other (accidental, sharing blades, surgery) 44.1% (26) 46.3% (101) 0.81
Time in Years since HCV Diagnosis (mean ± SD) 6.62 ± 3.69 6.39 ± 3.74 0.67
Virus genotype% (N)
1 72.9% (43) 75.1% (160)
2 3.4% (2) 2.8% (6)
3 22% (13) 22.1% (47)
4 1.7% (1) 0% (0) 0.38
Inﬂammatory activity (METAVIR)% (N)
A0 23.5% (12) 26.6% (51)
A1 39.2% (20) 31.8% (61)
A2 27.5% (14) 30.2% (58)
A3 9.8% (5) 11.5% (22) 0.89
Fibrosis (METAVIR)% (N)
F0–F1 1.9% (1) 14.1% (28)
F2–F3 81.1% (43) 70.2% (139)
F4 17.0% (9) 15.7% (31) 0.03
Duration of the last antiviral therapy (months)
6 40.7% (24) 45% (98)
12 59.3% (35) 55% (120) 0.65
Antiviral Therapy
Pegylated IFN-a plus RBV% (N) 84.7% (50) 80.6% (175) 0.57
Number of IFN-a trials% (N)
1 78% (46) 83.5% (182)
2 or more 22% (13) 16.5% (36) 0.33
Successful antiviral therapy% (N) 44.8% (26) 46.5% (99) 0.88
Time in years since therapy termination (mean ± SD) 2.15 ± 1.41 2.54 ± 1.73 0.07
Presence of any other general medical condition 62.7% (37) 64.2% (140) 0.87
Abbreviations: IFN-a, interferon-alpha; SD, standard deviation; HCV, hepatitis C virus; RBV, ribavirin.
Table 2
Psychiatric and psychometric characteristics of the sample concerning its IFN-a-related depression status, according to the MINI.
Characteristics IFN-a-related Depression p value
Yes No
Current major depression% (N) 15.3% (9) 1.8% (4) <0.001
Lifetime major depression non-related to IFN-a% (N) 15.3% (9) 8.7% (19) 0.14
Current anxiety disorder% (N) 32.2% (19) 13.3% (29) 0.002
Lifetime substance abuse or Dependence% (N) 44.1% (26) 33.5% (73) 0.16
Report of current or past psychiatric treatment% (N) 35.6% (21) 13.8% (30) <0.001
Lifetime suicidal attempt% (N) 5.1% (3) 3.7% (8) 0.7
Current suicide risk according to the MINI% (N)
Low 91.5% (54) 98.2% (214)
Moderate 1.7% (1) 0.5% (1)
High 6.8% (4) 1.4% (3) 0.03
Family history of any psychiatric disorder% (N) 79.7% (47) 67.9% (148) 0.1
Family history of depression% (N) 15.3% (9) 10.1% (22) 0.25
Family history of suicide% (N) 8.5% (5) 7.3% (16) 0.78
Current BDI scores (mean ± SD) 17.7 ± 12.2 9.3 ± 8.4 <0.001
Current HADS scores (mean ± SD) 16.6 ± 7.5 10.0 ± 7.1 <0.001
Abbreviations: IFN-a, interferon-alpha; SD, standard deviation; MINI, Mini International Neuropsychiatric Interview; BDI, Beck Depression Inventory; HADS, Hospital Anxiety
and Depression Scale.
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without IFN-a-related depression (p > 0.05). Genotype and allele
frequencies for the three studied markers in both groups are
shown in Table 3. No association with the diagnosis of major
depressive episode during the course of IFN-a therapy was ob-
served genotype or allele-wise (p > 0.05).
Multivariate logistic regression analyses including ﬁbrosis,
current major depression, current anxiety disorder, report of psy-
chiatric treatment, current suicide risk, current BDI and HADS
scores, as well as the genotype groups and genetic ancestry estima-
tions, conﬁrmed the lack of association between the rs10089084
(OR = 1.17; 95% CI = 0.56–2.45; p = 0.676) and the rs3824259 poly-
morphisms (OR = 1.10; 95% CI = 0.50–2.41; p = 0.810), and the
diagnosis of IFN-a-related depression.3.4. Discussion
The enzyme IDO is known to act by metabolizing tryptophan in
serotonin and kynurenine. Although the role of IDO in IFN-a-
induced depression is supported by many studies (Wichers and
Maes, 2002; Bonaccorso et al., 2002; Capuron and Miller, 2004;
Comai et al., 2011), to thebest of ourknowledge, this is theﬁrst study
to investigate the inﬂuence of the genetic variants of this enzyme
and the diagnosis of major depression during the course of IFN-a
therapy. Contrary to our hypothesis, no association between the
rs3824259, rs10089084, and rs35099072 polymorphisms and IFN-
a-related depression was indentiﬁed.
We accounted for the potential bias related to population strati-
ﬁcation in the Brazilian ethnically heterogeneous population using
thirty-ﬁve AIMs that show large differences in allele distribution
among the threemain ethnic groups (European, African and Indige-
nous). However, the inclusion of the estimated ancestry did not af-
fect the genetic association results. It is important to note that the
high level of admixture found in our sample has a strong inﬂuence
on the haplotype structure of the gene, and therefore other SNPs in
and around the gene should be further evaluated before any conclu-
sion regarding the effect of the IDO gene variation in the predisposi-
tion of IFN-a-related depression can be reached. In addition, power
calculation revealed that the total sample has approximately 80%
power to detect differences in genotype group frequency > 18%,
assuming the frequency of 46.8% and 63.5% of the CG/GG and GT/
GG genotype groups among individuals who have not developed
IFN-a-related depression, for the rs10089084 and rs3824259,
respectively.Table 3
Genotype and Allele frequencies concerning the IFN-a-related depression status of
the patients.
Genotypes and Alleles IFN-a-related Depression p value
Yes No
rs10089084
CC 52.5% (31) 53.2% (115) 1.0
CG/GG 47.5% (28) 46.8% (101)
C 69.5% (82) 72% (311) 0.65
G 30.5% (36) 28% (121)
rs3824259
TT 41.8% (23) 36.5% (77) 0.5
GT/GG 58.2% (32) 63.5% (134)
T 65.5% (72) 58.3% (246) 0.19
G 34.5% (38) 41.7% (176)
rs35099072
GG 100% (56) 99.1% (212) 1.0
GA 0 0.9% (2)
G 100% (112) 99.5% (426) 1.0
A 0 0.5% (2)
Abbreviation: IFN-a, interferon-alpha.The fact that an association between these polymorphisms and
the diagnosis of depression related to IFN-a therapy was not found
in our HCV patients suggests that other genetic variations either
inﬂuence or are inﬂuenced by IDO and its metabolites’ actions. In-
deed, polymorphisms of pro-inﬂammatory cytokines that may be
associated to the overstimulation of IDO, such as IL-6 (Bull et al.,
2009) and IL-28B (Lotrich et al., 2010), of the IFN-a-receptor 1 (Yos-
hida et al., 2005), the serotonin transporter (5-HTT) (Bull et al., 2009;
Lotrich et al., 2009), and the serotonin-1A receptor gene (HTR1A)
(Kraus et al., 2007) have been investigated and seem to play a role
in the vulnerability to IFN-a-induced depression. Moreover, genetic
variations of phospholipase A2 (PLA2) and cyclooxygenase-2
(COX2), the two key enzymes of the polyunsaturated fatty acid
(PUFA) metabolism and prostaglandin E2 (PGE2) synthesis, have
also increased the risk of IFN-a-induceddepression in a recent study
(Su et al., 2010).
Nevertheless, a number of relevant clinical ﬁndings pertaining
to the Brazilian sample should be noted. Importantly, regarding
the natural course of this substance-related depression, our study
raises questions related to the possibility of psychic consequences
to IFN-a administration lasting many years after the therapy ces-
sation. In fact, only 4 of the 13 patients who were depressed at
the evaluation did not meet criteria for IFN-a-related major
depression. Usually known to be limited to the regular 6 to
12 months of treatment (Capuron et al., 2002), this adverse effect
may impose persistent psychopathology on at least 15% (9 out of
59) of the depressed patients up to 2 years after antiviral therapy
termination. Therefore, we have recently hypothesized that, in
some vulnerable patients, IFN-a may trigger a pathophysiological
pathway which may become autonomous and maintain the
depressive symptoms, even in the absence of the exogenous cyto-
kine, generating a chronic depressive episode (Galvão-de Almeida
et al., 2010b).
Concerning the relevant association of this adverse effect and
the diagnosis of current anxiety disorder, we speculate that since
depression and anxiety have been proposed as parts of the
same psychopathological spectrum (Gorman, 1996–1997; Nestadt
et al., 2003), the latter may represent sequelae of IFN-a-triggered
depression (Bonaccorso et al., 2001). Another explanation is that
this comorbidity reveals an artifact of the current nosological
classiﬁcations, and consequently of the diagnostic instrument that
was applied.
The main limitation of our study is that these patients were not
evaluated before the antiviral therapy. Consequently, although
patients previously diagnosed with a mood disorder have been
excluded, we cannot afﬁrm that the depressive symptoms began
only after cytokine initiation. In order to contemplate this limitation,
we have chosen to use the term ‘‘IFN-a-related depression’’, rather
than ‘‘IFN-a-induced depression’’. Moreover, it should also be noted
that a placebo or a control group of IFN-a-naïve HCV patients was
not included to assure that diagnosed major depression episodes
were really a consequence of the cytokine exposure, and not only
part of the natural course of chronic hepatitis C. In addition, it is pos-
sible that the relatively low number of patients found to be diag-
nosed with depression during antiviral therapy (Capuron et al.,
2002; Asnis et al., 2003) may be a result of memory bias. In fact,
the variable Time since Therapy Termination showed an association
trend with the main outcome (p = 0.07), suggesting that the longer
the time since the endof the last treatment, the less likely thepatient
would be to fulﬁll the criteria for IFN-a-related depression. Our aim
was to guarantee a higher number of patients assessed; however,
prospective studies aremore adequate for the purpose of evaluating
psychopathology induced by IFN-a. In this study, amajor risk factor
for this adverse effect, which is baseline subclinical affective symp-
toms, could not be evaluated (Hauser et al., 2002; Dieperink et al.,
2003).
1496 A. Galvão-de Almeida et al. / Brain, Behavior, and Immunity 25 (2011) 1491–1497Our results corroborate the results of many other studies sug-
gesting that the development of this substance-induced depression
is not related to gender, age, route of infection, type of IFN used,
result of the antiviral treatment, past history of substance use dis-
orders, depression or any psychiatric disorder not related to cyto-
kine administration, and family history of mood disorder
(Horikawa et al., 2003; Schaefer et al., 2002; Capuron and Ravaud,
1999; Otsubo et al., 1997). These data are in contrast to a recent
study which found that female gender independently predicted
the emergence of major depression during IFN-a treatment in hep-
atitis C (Leutscher et al., 2010).
On the other hand, the higher severity of liver ﬁbrosis showed a
signiﬁcant association with the diagnosis of IFN-a-related depres-
sion in our sample. Otsubo et al. (1997) also evaluated the effect of
this variable in a prospective design study examining a sample of
85 Japanese patients and could not ﬁnd evidence of such associa-
tion. In addition to population-speciﬁc characteristics, and a smal-
ler sample size, differently from our approach, the previous study
used DSM-III-R criteria and Hamilton Depression Scale scores to
reach major depression diagnosis. Combined, these factors may
explain the discordant results. Additionally, it’s reasonable to as-
sume that severe liver dysfunctions may result in more neuroveg-
etative symptoms, cognitive impairment, and monoamine
disturbance in CNS, predisposing the fulﬁllment of major depres-
sion diagnosis (Quarantini et al., 2009).
Additionally, as other studies with Brazilian samples demon-
strated (Parana et al., 1999; Quarantini et al., 2006), the main
routes of infection of HCV in our study were blood transfusion
and sharing syringes to use vitamin complexes. Therefore, it may
not be possible to extend our ﬁndings to groups of patients with
hepatitis C including a signiﬁcant percentage of illicit intravenous
drug users, the main source of HCV infection worldwide (Lavanchy,
2009).
In summary, since the role of IDO in the pathophysiology of this
cytokine-triggered depression has proven relevant (Comai et al.,
2011), the inability to identify any association between the
selected polymorphisms and our diagnosis of major depression re-
lated to IFN-a plus RBV therapy does not completely exclude the
possibility of the role of genetic variants in the modulation of
IFN-a response. Although IDO polymorphisms evaluated in this
study may not be directly involved in the vulnerability to IFN-a-
related depression, additional variants in and around the gene,
not in close disequilibrium linkage with the present ones, should
be examined. Our results also suggest that investigating neuropsy-
chiatric adverse effects that may develop or persist years after the
therapy termination is as important as detecting these adverse
effects during the antiviral therapy.
Finally, prospective pharmacogenetic studies are warranted to
continue investigation of the impact of IDO polymorphisms on
the development of IFN-a-induced depression; and the search for
other candidate genes that may ﬁll the gaps in prediction of this
substance-induced affective disorder must continue.
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